At a glance
ClinicalIndex Comparison RecordN/ACompleted· 34 enrolled
Drug / intervention
Lanthanum carbonatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term, Observational Study to Monitor Mortality, Bone-related Adverse Events and the Safety of Subjects Who Were Recruited Into Study SPD405-309
In Brief
An observational study evaluating Lanthanum carbonate for Hyperphosphatemia. Completed, enrolled 34 participants across 19 sites in 3 countries.
Detailed Summary
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an additional 5 years. Patients were being observed for any bone adverse events or other serious adverse events, as well as the collection of mortality data.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHyperphosphatemia
CountriesGermany, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedNov 2007
Primary CompletionAug 2010
TodayJul 2026
First PostedNov 14, 2007
Enrollment StartMar 15, 2007
Primary CompletionAug 31, 2010
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.6 years ago
Interventions
Lanthanum carbonatedrug